Alexion Pharmaceuticals (ALXN) Raised to Outperform at Robert W. Baird

Alexion Pharmaceuticals (NASDAQ:ALXN) was upgraded by stock analysts at Robert W. Baird from a “neutral” rating to an “outperform” rating in a research report issued on Monday, MarketBeat.com reports. The brokerage presently has a $150.00 target price on the biopharmaceutical company’s stock. Robert W. Baird’s target price would indicate a potential upside of 29.21% from the stock’s previous close.

Several other analysts have also recently commented on the stock. TheStreet cut shares of Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Friday, November 10th. Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 price target on the stock in a research note on Tuesday, October 31st. Royal Bank of Canada assumed coverage on shares of Alexion Pharmaceuticals in a research note on Thursday, September 14th. They issued an “outperform” rating and a $161.00 price target on the stock. Credit Suisse Group reiterated a “buy” rating and issued a $166.00 price target on shares of Alexion Pharmaceuticals in a research note on Tuesday, December 12th. Finally, Stifel Nicolaus decreased their price target on shares of Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating on the stock in a research note on Tuesday, October 24th. Three analysts have rated the stock with a hold rating, nineteen have given a buy rating and two have assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $155.70.

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded up $0.33 during trading on Monday, reaching $116.09. 1,774,673 shares of the company traded hands, compared to its average volume of 2,298,998. The company has a market cap of $25,861.94, a P/E ratio of 23.67, a P/E/G ratio of 1.26 and a beta of 1.18. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.96 and a quick ratio of 2.51. Alexion Pharmaceuticals has a one year low of $96.18 and a one year high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, topping the consensus estimate of $1.32 by $0.12. The company had revenue of $859.00 million during the quarter, compared to the consensus estimate of $864.34 million. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. Alexion Pharmaceuticals’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.23 EPS. analysts anticipate that Alexion Pharmaceuticals will post 4.82 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Fiduciary Trust Co. purchased a new stake in shares of Alexion Pharmaceuticals during the 2nd quarter valued at about $111,000. Valeo Financial Advisors LLC purchased a new stake in shares of Alexion Pharmaceuticals during the 3rd quarter valued at about $147,000. Penserra Capital Management LLC raised its position in shares of Alexion Pharmaceuticals by 13.0% during the 2nd quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 144 shares in the last quarter. Dupont Capital Management Corp purchased a new stake in shares of Alexion Pharmaceuticals during the 3rd quarter valued at about $156,000. Finally, BT Investment Management Ltd purchased a new stake in shares of Alexion Pharmaceuticals during the 3rd quarter valued at about $165,000. Hedge funds and other institutional investors own 94.33% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Alexion Pharmaceuticals (ALXN) Raised to Outperform at Robert W. Baird” was originally reported by American Market News and is the property of of American Market News. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://www.americanbankingnews.com/2017/12/18/alexion-pharmaceuticals-alxn-raised-to-outperform-at-robert-w-baird.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).